Since I involved in other bio-marker development, I can do calculation based on duplicated analysis revenue. Generally, people get tumors and mostly they are not the malignant type to prove they have to do the tests. BD1 method is well advanced and detects very early stage. When they sell the kit for the purpose they can make a very good return. I expect some agreement with diagnostic kit distributors with BD1 and this may happen any time. When the kit becomes popular return will be very high and early-stage expect 10% of the following. Always profit in this area at least 200% and same as pharmaceuticals.
In Australia only can make Revenue100,000 subjects x $200 = 20000000 = 20 million
USA
1000000 x $200 = 200 Million
Europe
1000000 x $200 = 200 million
Since I involved in other bio-marker development, I can do...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.0¢ |
Change
0.050(8.20%) |
Mkt cap ! $60.73M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 66.0¢ | 61.0¢ | $296.4K | 471.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11184 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.0¢ | 23617 | 1 |
View Market Depth
| Last trade - 15.57pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
0.050 ( 7.75 %) |
||||
| Open | High | Low | Volume | ||
| 63.5¢ | 64.5¢ | 62.0¢ | 31571 | ||
| Last updated 15.19pm 14/06/2024 ? | |||||
| IIQ (ASX) Chart |